Obesity, Abdominal: Clinical Trials

22 trials for Obesity, Abdominal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 completed, 1 recruiting, 1 terminated. 22 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 222Completed 20, Recruiting 1, Terminated 1
Phase 31Completed 1

Follow Obesity, Abdominal: new trials by email Literature Review of Obesity, Abdominal trials Research Report on Obesity, Abdominal

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Tesamorelin, Placebo, Exercise - HIV-1-infection, Frailty
Phase 2RecruitingMassachusetts General Hospital1002025-07-102026-05-19
Metformin Effect on Brain Function in Insulin Resistant Elderly People
Metformin Hydrochloride, Placebo Oral Tablet - Insulin Resistance, Obesity
Phase 2CompletedMayo Clinic402019-03-152024-06-18
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Tesamorelin, Identical Placebo - Non-Alcoholic Fatty Liver Disease, Obesity
Phase 2CompletedMassachusetts General Hospital512019-01-172025-11-20
Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity
Surimi intervention, Placebo - Obesity, Abdominal
Phase 2CompletedTechnological Centre of Nutrition and Health, Spain1202018-08-022022-03-02
Vitamin D Supplementation on Metabolic Syndrome Indicators Among Older Adults, Alborz Province, Iran
D-vitin, soft gelatin capsule (vitamin D3,50000 IU), Placebo vitamin D3 - Vitamin D Deficiency, Diabetes Mellitus
Phase 2CompletedAlborz Medical University1202017-02-102018-01-16
Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity
Banaba, placebo - Metabolic Syndrome X
Phase 2CompletedUniversity of Guadalajara242015-01-012021-01-14
Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome
Ursolic acid, Placebo - Metabolic Syndrome X
Phase 2CompletedUniversity of Guadalajara242014-09-012020-10-08
Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin
Placebo, Gymnema Sylvestre - Metabolic Syndrome
Phase 2CompletedUniversity of Guadalajara242013-02-012019-06-18
Effects of Acipimox on Mitochondrial Function in Obesity
Acipimox, Placebo - Abdominal Obesity, Insulin Resistance
Phase 2CompletedMassachusetts General Hospital392012-05-012016-03-01
Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
Resveratrol, Placebo - Metabolic Syndrome X
Phase 2CompletedUniversity of Guadalajara242012-04-012020-09-17
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
GFT505 80mg, Placebo - Insulin Resistance, Abdominal Obesity
Phase 2CompletedGenfit222011-01-012012-09-24
Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss
Diet A, Diet B, Physiotherapy - Abdominal Obesity, Cardiovascular Diseases
Phase 2 / Phase 3CompletedLund University1052010-08-012017-06-20
Preventing Renal Functional Abnormalities With Calorie Restriction in Subjects With Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk
Caloric restriction, No intervention - Diabetes Mellitus
Phase 2CompletedMario Negri Institute for Pharmacological Research732009-09-012013-02-21
Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity.
GFT505 80mg, Placebo - Impaired Glucose Tolerance, Abdominal Obesity
Phase 2CompletedGenfit472009-06-012011-01-12
Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity
GFT505 80mg, Placebo - Atherogenic Dyslipidaemia, Abdominal Obesity
Phase 2CompletedGenfit962009-01-012011-01-07
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency
Phase 2CompletedMassachusetts General Hospital602008-07-012017-12-13
Dose Ranging Study of the Effects of Alpha Lipoic Acid on Oxidative Stress
Alpha lipoic acid at 3 doses compared to placebo - Metabolic Syndrome
Phase 2CompletedJohns Hopkins University772008-03-012012-10-01
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Aliskiren, Amlodipine, Placebo of Aliskiren - Hypertension, Abdominal Obesity
Phase 2TerminatedNovartis462007-06-012014-09-10
Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference
High Fructose Corn Syrup, Sucromalt - Abdominal Obesity
Phase 2CompletedUniversity of Toronto282006-09-012007-08-14
Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
Topical testosterone gel 10 g/day - Aging, Obesity
Phase 2CompletedUniversity of Southern California222006-08-012019-08-26

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Insulin Resistance (10)  ·  Hypertension (6)  ·  Obesity (6)  ·  Metabolic Syndrome (5)  ·  Glucose Intolerance (4)  ·  Diabetes Mellitus, Type 2 (3)  ·  Diabetes Mellitus (2)  ·  Cardiovascular Diseases (1)  ·  Cognitive Dysfunction (1)  ·  Dwarfism, Pituitary (1)  ·  Fatty Liver (1)  ·  Frailty (1)  ·  Hypercholesterolemia (1)  ·  Hypertriglyceridemia (1)

Broader conditions

Body Weight (22)  ·  Nutrition Disorders (22)  ·  Nutritional and Metabolic Diseases (22)  ·  Overnutrition (22)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Signs and Symptoms (22)  ·  Overweight (21)  ·  Glucose Metabolism Disorders (16)  ·  Metabolic Diseases (16)  ·  Obesity (16)  ·  Hyperinsulinism (11)  ·  Endocrine System Diseases (6)  ·  Vascular Diseases (6)  ·  Cardiovascular Diseases (5)  ·  Hyperglycemia (4)

Interventions

2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (3)  ·  tesamorelin (3)  ·  Exercise (2)  ·  Growth Hormone-Releasing Hormone (2)  ·  Amlodipine (1)  ·  Caloric Restriction (1)  ·  Cholecalciferol (1)  ·  Ghrelin (1)  ·  Gurmarin protein, Gymnema sylvestre (1)  ·  High Fructose Corn Syrup (1)  ·  Hydrochlorothiazide (1)  ·  Metformin (1)  ·  Physical Therapy Modalities (1)  ·  Resveratrol (1)  ·  Testosterone (1)

Sponsors

Massachusetts General Hospital (4)  ·  University of Guadalajara (4)  ·  Genfit (3)  ·  Alborz Medical University (1)  ·  Johns Hopkins University (1)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)  ·  Lund University (1)  ·  Mario Negri Institute for Pharmacological Research (1)  ·  Mayo Clinic (1)  ·  Novartis (1)  ·  Technological Centre of Nutrition and Health, Spain (1)  ·  UmeĆ„ University (1)  ·  University of Southern California (1)  ·  University of Toronto (1)

Countries

United States (6)  ·  France (3)  ·  Mexico (3)  ·  Sweden (2)  ·  Canada (1)  ·  Germany (1)  ·  Iran (1)  ·  Italy (1)  ·  Romania (1)  ·  Spain (1)  ·  Tunisia (1)

Top investigators

Fred R Sattler, MD (1)  ·  Jan Eriksson, MD, PhD (1)  ·  K Sreekumaran Nair, M.D., Ph.D. (1)  ·  Kristine M. Erlandson, MD (1)  ·  Lindsay T. Fourman, MD (1)  ·  Pamela Ouyang, MBBS (1)  ·  Staffan Lindeberg, MD PhD (1)

Results publications

PMID 23703580, PMID 21816979, PMID 10480510, PMID 10868854, PMID 10963727, PMID 11411567, PMID 11556815, PMID 12523673, PMID 12622244, PMID 15168555, PMID 15333514, PMID 16054141, PMID 16626303, PMID 1695875, PMID 17069794, PMID 17086191, PMID 17112576, PMID 17578889, PMID 18266981, PMID 19100718, PMID 19819963, PMID 20463039, PMID 20812281, PMID 21261640, PMID 21385509, PMID 21569266, PMID 21673955, PMID 21688389, PMID 22219517, PMID 2259217, PMID 22911568, PMID 22913271, PMID 23015655, PMID 23715754, PMID 23852298, PMID 23876572, PMID 24178787, PMID 24291224, PMID 2451154, PMID 24511547, PMID 24856809, PMID 25284929, PMID 25392748, PMID 25668616, PMID 26691888, PMID 34726501, PMID 35643872, PMID 38639002, PMID 41039470, PMID 42419889

NIH funding

2008 (1), 2009 (1), R01HL085268 (1), R21AG060139 (1)